Cargando…

Malignancy validation in a United States registry of rheumatoid arthritis patients

BACKGROUND: Physician reporting is commonly used to ascertain adverse events or outcomes measured in epidemiologic studies. However, little is known on the accuracy of physician reported malignancies compared to pertinent medical record review in large cohort studies. METHODS: The Consortium of Rheu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Mark C, Furer, Victoria, Hochberg, Marc C, Greenberg, Jeffrey D, Kremer, Joel M, Curtis, Jeff R, Reed, George, Harrold, Leslie, Solomon, Daniel H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403943/
https://www.ncbi.nlm.nih.gov/pubmed/22651246
http://dx.doi.org/10.1186/1471-2474-13-85
_version_ 1782238952494727168
author Fisher, Mark C
Furer, Victoria
Hochberg, Marc C
Greenberg, Jeffrey D
Kremer, Joel M
Curtis, Jeff R
Reed, George
Harrold, Leslie
Solomon, Daniel H
author_facet Fisher, Mark C
Furer, Victoria
Hochberg, Marc C
Greenberg, Jeffrey D
Kremer, Joel M
Curtis, Jeff R
Reed, George
Harrold, Leslie
Solomon, Daniel H
author_sort Fisher, Mark C
collection PubMed
description BACKGROUND: Physician reporting is commonly used to ascertain adverse events or outcomes measured in epidemiologic studies. However, little is known on the accuracy of physician reported malignancies compared to pertinent medical record review in large cohort studies. METHODS: The Consortium of Rheumatology Researchers of North America (CORRONA) registry gathers physician-completed questionnaires for rheumatoid arthritis (RA) patients, including request for information on incident malignancies, approximately every three months. For incident malignancies reported from October 1st, 2001, through December 31st, 2007, we retrospectively requested completion of a Targeted Adverse Event (TAE) form for additional information as well as primary source documents to adjudicate the malignancy reports. CORRONA has employed a prospective request for source documentation for these events since 2008. We classified each malignancy as definite, probable, possible, or not a malignancy. RESULTS: From 20,837 RA patients enrolled in CORRONA, 461 incident malignancies were initially reported on physician questionnaires. After review of returned source documents with adjudication, 234 were deemed definite, 69 probable, 101 possible, and 57 not an incident malignancy. The positive predictive value (PPV) of initial physician report of a malignancy versus “definite or probable” malignancy based on adjudication was 0.66 (95% CI 0.61 - 0.70). The PPV was 0.68 (95% CI 0.63 – 0.72) when the subsequent TAE form also confirmed the presence of malignancy. When possible malignancies were included, the PPV of physician-reported malignancies without a subsequent TAE form increased to 0.86 (0.83 – 0.89), and with a subsequent TAE form, 0.89 (0.85-0.91). CONCLUSION: Twelve percent of initial physician reports of incident malignancy could not be confirmed with review of source documents. The most common reason for lack of confirmation was inability to obtain documents or insufficient data in source materials. These results suggest that timely collection of relevant medical records and an adjudication process are required to improve the accuracy of cancer reporting in epidemiologic studies.
format Online
Article
Text
id pubmed-3403943
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34039432012-07-25 Malignancy validation in a United States registry of rheumatoid arthritis patients Fisher, Mark C Furer, Victoria Hochberg, Marc C Greenberg, Jeffrey D Kremer, Joel M Curtis, Jeff R Reed, George Harrold, Leslie Solomon, Daniel H BMC Musculoskelet Disord Research Article BACKGROUND: Physician reporting is commonly used to ascertain adverse events or outcomes measured in epidemiologic studies. However, little is known on the accuracy of physician reported malignancies compared to pertinent medical record review in large cohort studies. METHODS: The Consortium of Rheumatology Researchers of North America (CORRONA) registry gathers physician-completed questionnaires for rheumatoid arthritis (RA) patients, including request for information on incident malignancies, approximately every three months. For incident malignancies reported from October 1st, 2001, through December 31st, 2007, we retrospectively requested completion of a Targeted Adverse Event (TAE) form for additional information as well as primary source documents to adjudicate the malignancy reports. CORRONA has employed a prospective request for source documentation for these events since 2008. We classified each malignancy as definite, probable, possible, or not a malignancy. RESULTS: From 20,837 RA patients enrolled in CORRONA, 461 incident malignancies were initially reported on physician questionnaires. After review of returned source documents with adjudication, 234 were deemed definite, 69 probable, 101 possible, and 57 not an incident malignancy. The positive predictive value (PPV) of initial physician report of a malignancy versus “definite or probable” malignancy based on adjudication was 0.66 (95% CI 0.61 - 0.70). The PPV was 0.68 (95% CI 0.63 – 0.72) when the subsequent TAE form also confirmed the presence of malignancy. When possible malignancies were included, the PPV of physician-reported malignancies without a subsequent TAE form increased to 0.86 (0.83 – 0.89), and with a subsequent TAE form, 0.89 (0.85-0.91). CONCLUSION: Twelve percent of initial physician reports of incident malignancy could not be confirmed with review of source documents. The most common reason for lack of confirmation was inability to obtain documents or insufficient data in source materials. These results suggest that timely collection of relevant medical records and an adjudication process are required to improve the accuracy of cancer reporting in epidemiologic studies. BioMed Central 2012-05-31 /pmc/articles/PMC3403943/ /pubmed/22651246 http://dx.doi.org/10.1186/1471-2474-13-85 Text en Copyright ©2012 Fisher et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fisher, Mark C
Furer, Victoria
Hochberg, Marc C
Greenberg, Jeffrey D
Kremer, Joel M
Curtis, Jeff R
Reed, George
Harrold, Leslie
Solomon, Daniel H
Malignancy validation in a United States registry of rheumatoid arthritis patients
title Malignancy validation in a United States registry of rheumatoid arthritis patients
title_full Malignancy validation in a United States registry of rheumatoid arthritis patients
title_fullStr Malignancy validation in a United States registry of rheumatoid arthritis patients
title_full_unstemmed Malignancy validation in a United States registry of rheumatoid arthritis patients
title_short Malignancy validation in a United States registry of rheumatoid arthritis patients
title_sort malignancy validation in a united states registry of rheumatoid arthritis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403943/
https://www.ncbi.nlm.nih.gov/pubmed/22651246
http://dx.doi.org/10.1186/1471-2474-13-85
work_keys_str_mv AT fishermarkc malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT furervictoria malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT hochbergmarcc malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT greenbergjeffreyd malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT kremerjoelm malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT curtisjeffr malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT reedgeorge malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT harroldleslie malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients
AT solomondanielh malignancyvalidationinaunitedstatesregistryofrheumatoidarthritispatients